Literature DB >> 29528698

Opioids in Cardiovascular Disease: Therapeutic Options.

Hemangi Rawal1, Bhoomika M Patel1.   

Abstract

The World Health Organization suggests that the cardiovascular diseases (CVDs) are the major cause of mortality and account for two-thirds of the deaths all over the world. These diseases kill about 17 million people every year and 3 in every 10 deaths are due to these diseases. The past decade has seen considerable improvements in diagnosis as well as treatment of various heart diseases. Various new therapeutic targets are being identified through in-depth knowledge of the disease mechanisms which has favored the testing of new strategies leading to newer treatment options. Opioid peptides and G-protein-coupled opioid receptors (ORs) have been previously studied widely in terms of central nervous system actions in mitigating the pain and drug abuse. The OR agonism or antagonism induces cytoprotective states in the myocardium, rendering these receptors as an attractive target for protection of heart from the fatal heart diseases. The opioids can provide an extended window of protection of the heart from various diseases. Although the mechanisms may not be fully understood, they seem to play a crucial role in various CVDs such as hypertension, hyperlipidemia, ischemic heart disease myocardial ischemia, and congestive heart failure. Since these compounds are already being used in acute and chronic pain, soon these compounds might be approved for use as cardioprotective agents. The following review focuses on the new information acquired on the role of the ORs in various CVDs.

Entities:  

Keywords:  cardiovascular diseases; opioid agonist; opioid antagonist; opioid receptors

Mesh:

Substances:

Year:  2018        PMID: 29528698     DOI: 10.1177/1074248418757009

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol Ther        ISSN: 1074-2484            Impact factor:   2.457


  8 in total

1.  Remifentanil versus dexmedetomidine for treatment of cardiac surgery patients with moderate to severe noninvasive ventilation intolerance (REDNIVIN): a prospective, cohort study.

Authors:  Guang-Wei Hao; Jing-Chao Luo; Yan Xue; Guo-Guang Ma; Ying Su; Jun-Yi Hou; Shen-Ji Yu; Kai Liu; Ji-Li Zheng; Guo-Wei Tu; Zhe Luo
Journal:  J Thorac Dis       Date:  2020-10       Impact factor: 2.895

2.  Opioids Cause Sex-Specific Vascular Changes via Cofilin-Extracellular Signal-Regulated Kinase Signaling: Female Mice Present Higher Risk of Developing Morphine-Induced Vascular Dysfunction than Male Mice.

Authors:  Soyoung Cheon; Jeremy C Tomcho; Jonnelle M Edwards; Nicole R Bearss; Emily Waigi; Bina Joe; Cameron G McCarthy; Camilla F Wenceslau
Journal:  J Vasc Res       Date:  2021-09-14       Impact factor: 2.045

3.  Exploring Unconventional Risk-Factors for Cardiovascular Diseases: Has Opioid Therapy Been Overlooked?

Authors:  Oluwabunmi Ogungbe; Luma Akil; Hafiz A Ahmad
Journal:  Int J Environ Res Public Health       Date:  2019-07-18       Impact factor: 3.390

4.  Comparison of clinical safety and efficacy of dexmedetomidine, remifentanil, and propofol in patients who cannot tolerate non-invasive mechanical ventilation: A prospective, randomized, cohort study.

Authors:  Mine Altınkaya Çavuş; Serife Gökbulut Bektaş; Sema Turan
Journal:  Front Med (Lausanne)       Date:  2022-08-30

Review 5.  NRF2 in Cardiovascular Diseases: a Ray of Hope!

Authors:  Ruju Vashi; Bhoomika M Patel
Journal:  J Cardiovasc Transl Res       Date:  2020-11-25       Impact factor: 4.132

Review 6.  Management of Opioid-Induced Constipation and Bowel Dysfunction: Expert Opinion of an Italian Multidisciplinary Panel.

Authors:  Roberto De Giorgio; Furio Massimino Zucco; Giuseppe Chiarioni; Sebastiano Mercadante; Enrico Stefano Corazziari; Augusto Caraceni; Patrizio Odetti; Raffaele Giusti; Franco Marinangeli; Carmine Pinto
Journal:  Adv Ther       Date:  2021-06-04       Impact factor: 3.845

7.  Neprilysin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study.

Authors:  Elena Revuelta-López; Julio Núñez; Paloma Gastelurrutia; Germán Cediel; James L Januzzi; Nasrien E Ibrahim; Michele Emdin; Roland VanKimmenade; Domingo Pascual-Figal; Eduardo Núñez; Frank Gommans; Josep Lupón; Antoni Bayés-Genís
Journal:  ESC Heart Fail       Date:  2020-02-11

8.  De novo variants in exomes of congenital heart disease patients identify risk genes and pathways.

Authors:  Cigdem Sevim Bayrak; Peng Zhang; Martin Tristani-Firouzi; Bruce D Gelb; Yuval Itan
Journal:  Genome Med       Date:  2020-01-15       Impact factor: 11.117

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.